Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018616 | 0.93 | CASP3 (0.49) | CASP3MDM2MDM4TP53TLR2 | |
| SCHEMBL29430965 | 0.89 | CASP3 (0.47) | CASP3MDM2MDM4TP53TLR2 | |
| SCHEMBL29431036 | 0.89 | CASP3 (0.53) | CASP3MDM2MDM4TP53TLR2 | |
| SCHEMBL29462654 | 0.88 | CASP3 (0.55) | CASP3MDM2MDM4TP53TLR2 | |
| SCHEMBL29169309 | 0.87 | MDM4 (0.56) | CASP3MDM2MDM4TP53TLR2 | |
| SCHEMBL29169311 | 0.87 | MDM4 (0.56) | CASP3MDM2MDM4TP53TLR2 | |
| SCHEMBL29462951 | 0.87 | CASP3 (0.49) | CASP3MDM2MDM4TP53TLR2 | |
| SCHEMBL29706223 | 0.87 | CASP3 (0.52) | CASP3MDM2MDM4TP53TLR2 | |
| SCHEMBL29693009 | 0.87 | CASP3 (0.59) | CASP3MDM2MDM4TP53 | |
| SCHEMBL30804341 | 0.86 | MME (0.53) | CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217922-A1 | MODULATORS OF SORTILIN ACTIVITY | VESPER BIO APS (DK) | 2024-07-04 | — | — | US | disclosed |
| CN-117677627-A | Sortilin activity modulators | 因苏森斯有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4326742-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022223805-A1 | MODULATORS OF SORTILIN ACTIVITY | INSUSENSE ApS (DK) | 2022-10-27 | — | — | WO | disclosed |
| EP-4079748-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217922-A1 | MODULATORS OF SORTILIN ACTIVITY | SORT1, SCARB1, NPC1 | CASP3 3460/4885MDM2 4765/4885MDM4 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.